Qiagen NV
NYSE:QGEN
Net Margin
Qiagen NV
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| NL |
|
Qiagen NV
NYSE:QGEN
|
10.2B USD |
4%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
151.8B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
140.8B USD |
16%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.7B CHF |
10%
|
|
| JP |
D
|
DNA Chip Research Inc
TSE:2397
|
7.4B JPY |
-5%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.3B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.4B USD |
9%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
193B CNY |
27%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.6B USD |
22%
|
Qiagen NV
Glance View
Qiagen NV, a luminary in the realm of biotechnology, navigates the intricate world of molecular diagnostics and testing with a blend of innovation and expertise. Originating in 1984 in the Netherlands, this company has grown into a formidable presence in the life sciences sector. Qiagen's journey revolves around its core mission: to enable advancements in science and healthcare by providing technologies and solutions that unlock molecular insights. At the heart of its operations lies a comprehensive portfolio of sample and assay technologies. These are critical tools for laboratories worldwide, instrumental in the isolation and preparation of nucleic acids, such as DNA and RNA. With these tools, researchers and clinicians can delve deeper into the molecular underpinnings of diseases, paving the way for breakthroughs in diagnostics and treatment. Qiagen’s financial engine is fueled by its diverse array of products and services, ranging from consumables like reagents and kits to sophisticated equipment for automating laboratory processes. Its diagnostic solutions are pivotal in areas like oncology, infectious diseases, and personalized medicine, enabling institutions to detect and analyze genetic information with precision. Additionally, Qiagen earns revenue by supporting pharmaceutical and biotech firms in their quest to discover and develop new drugs, ultimately contributing to safer, more effective treatments. The company also benefits from strategic collaborations and partnerships, continually expanding its influence and technological prowess. Through this multifaceted approach, Qiagen not only thrives in the competitive biotech landscape but also plays a critical role in transforming molecular data into actionable healthcare outcomes.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Qiagen NV's most recent financial statements, the company has Net Margin of 4.2%.
You don't have any saved screeners yet